AbCellera Biologics Inc.
ABCL
Rang in aandelen
#4229
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the... AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
Aandeelprijs
$11.66
Marktkapitalisatie
$3.78B
Verandering (1 dag)
-2.26%
Verandering (1 jaar)
98.99%
Land
CA
Handel AbCellera Biologics Inc. (ABCL)
Categorie
Healthcare
P/B-ratio voor AbCellera Biologics Inc. (ABCL)
P/B-ratio op October 2026 TTM: 4.22
Volgens de meest recente financiële rapporten en aandelenkoers van AbCellera Biologics Inc. is de huidige P/B-ratio (TTM) 4.22. Eind 2023 had het bedrijf een P/B-ratio van 1.43.
P/B-ratiohistoriek voor AbCellera Biologics Inc. van 2018 tot 2026
P/B-ratio aan het einde van elk jaar
| Jaar | P/B-ratio | Wijzigen |
|---|---|---|
| 2026 (TTM) | 4.22 | 414.44% |
| 2024 | 0.82 | -43.01% |
| 2023 | 1.43 | -38.80% |
| 2022 | 2.34 | -39.10% |
| 2021 | 3.84 | -70.56% |
| 2020 | 13.06 | -98.53% |
| 2019 | 885.28 | 15.51% |
| 2018 | 766.43 | 0.00% |
P/B-ratio voor vergelijkbare bedrijven of concurrenten
| Bedrijf | P/B-ratio | Verschil in P/B-ratio | Land |
|---|---|---|---|
| 6.251 | 48.18% |
US
|
|
| 13.2547 | 214.21% |
US
|
|
| 4.208 | -0.25% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | 46.56% |
NL
|
